Zika Virus Suspected To Be Transmitted Sexually; Premier Biomedical Increases Focus; Optimistic Their Patented Extracorporeal Methodology Could Be Most Effective Treatment

EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, noted that the CDC reported recently, via CNN, that sexual transmission of the Zika Virus has been identified in 14 additional cases. As a result of this information, Premier Biomedical is considering their priorities to investigate accelerated development of their patented extra-corporeal (outside the body) process in an effort to generate an effective treatment for the Zika virus. The envisioned treatment is a variation of their patented process, initially developed to treat viruses like AIDS and Ebola.

“Premier’s extracorporeal process has the distinct advantage that allows us to physically remove the Zika virus, which could eliminate dangerous side-effects associated with standard medical treatments.”

William A. Hartman, President and CEO, indicated, “Premier’s extracorporeal process has the distinct advantage that allows us to physically remove the Zika virus, which could eliminate dangerous side-effects associated with standard medical treatments.”

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, initially targeting the treatment of cancer. The Company’s common stock trades on the Over-The-Counter Bulletin Board under the ticker symbol “BIEI.” http://www.premierbiomedical.com/

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.